CFRA maintains a "Hold" rating for Novartis (NYSE:NVS) with a price target of $126, indicating stability in its stock value.Zacks Investment Research identifies Novartis as a top value stock, highlighting its potential for long-term investment success.With a market capitalization of approximately$241.14 billion and a slight increase in stock price, Novartis demonstrates solid fundamentals and a strong market position.Novartis (NYSE:NVS) is a global healthcare company based in Switzerland, known for its inn ...